; (C) require the methods used in, and the facilities and controls used for, the manufacture, processing, and packing of drugs in the country to be adequate to preserve the identity, quality, purity, and strength of the drugs; and (D) require the reporting of adverse reactions to drugs and establish procedures to recall, and withdraw approval of, drugs found not to be safe or effective. (f) Labeling Any qualifying insulin imported that meets the labeling requirements described in subsection (b)(5)(A)(iv) is deemed not misbranded for purposes of section 502. (g) Insulin testing laboratories The Secretary may approve one or more laboratories to conduct random testing of insulin sold by certified foreign sellers to assess the chemical authenticity of such insulin. (h) Unfair and discriminatory Acts and practices It is unlawful for a manufacturer, directly or indirectly (including by being a party to a licensing agreement or other agreement)— (1) to discriminate by charging a higher price for an insulin sold to a certified foreign seller that sells such insulin to an importer in accordance with this section than the price that is charged, inclusive of rebates or other incentives to the country from which the insulin is exported, to another person that is in the same country and that does not import such insulin into the United States in accordance with this section; (2) except with respect to an insulin on the drug shortage list under section 506E, discriminate by denying, restricting, or delaying supplies of an insulin to a certified foreign seller, on account of such seller's status as a certified foreign seller, that sells such insulin to an importer in accordance with this section, or by publicly, privately, or otherwise refusing to do business with such a certified foreign seller on account of such seller's status as a certified foreign seller